Research and Markets has announced the addition of the "Sinusitis - Pipeline Review, H2 2016" report to their offering.
'Sinusitis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies Universities.
Sinusitis pipeline therapeutics constitutes close to 18 molecules. Out of which approximately 18 molecules are developed by Companies.
Furthermore, the publisher says; Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from infection caused by a viral or bacterial infection or by an allergy Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder, such as HIV/AIDS or cystic fibrosis and another allergic condition.
It also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 3, 5 and 2 respectively.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/bpcznm/sinusitis
View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005761/en/Business Wire
Last updated on: 17/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.